Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.46 |
| ▸ | WNT3A | P56704 | 5/20 | 0.46 |
| ▸ | HTR1B | P28222 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669670 | 0.88 | NPC1 (0.47) | PKMNPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL13984172 | 0.86 | CYP4F2 (0.54) | CTNNB1WNT3AHTR1BCYP4Z1 | |
| SCHEMBL7442715 | 0.85 | HTR1B (0.50) | PKMNPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL29875194 | 0.85 | HTR1B (0.50) | PKMNPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL25216720 | 0.80 | HTR1B (0.49) | CTNNB1WNT3AHTR1BTAS1R3TAS1R1 | |
| SCHEMBL30427150 | 0.80 | HTR1B (0.49) | CTNNB1WNT3AHTR1BTAS1R3TAS1R1 | |
| SCHEMBL1922396 | 0.80 | HTR1B (0.50) | CTNNB1WNT3AHTR1BTAS1R3TAS1R1 | |
| SCHEMBL30426911 | 0.80 | HTR1B (0.50) | CTNNB1WNT3AHTR1BTAS1R3TAS1R1 | |
| SCHEMBL2042113 | 0.79 | PPID (0.58) | SMN1; SMN2CTNNB1WNT3AHTR1BALDH1A1 | |
| SCHEMBL5372809 | 0.78 | TRPM8 (0.41) | PKMNPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444296-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-116075300-A | Advantageous benzofuran compositions for mental disorders or mental enhancement | 泰科根公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161503-A2 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252538-A2 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2021-12-16 | — | — | WO | disclosed |
| US-5229381-A | Inhibitors of leukocyte enzyme elastase | MERCK & CO., INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0481671-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | PKM 1983/4885NPC1 3154/4885NFKB1 2639/4885 |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | PKM 1983/4885NPC1 3154/4885NFKB1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.